Pharmaceutical Technology
MAY 19, 2023
It received approval from the US Food and Drug Administration in October 2018. EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028.
European Pharmaceutical Review
MAY 2, 2023
billion in 2028, according to GlobalData’s Pharma Intelligence Center. Limiting progression of geographic atrophy via C5 inhibition Specifically, ACP, a complement C5 inhibitor, is an investigational drug for GA secondary to AMD and has significant potential to deliver value to a large and underserved patient base, according to Astellas.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 8, 2022
Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year. These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. Famy Life Sciences has an ophthalmology portfolio that complements Viatris.
Pharmaceutical Technology
JULY 12, 2022
The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.
Pharmaceutical Technology
AUGUST 16, 2022
In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.
Pharmaceutical Technology
SEPTEMBER 2, 2022
This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.
Pharmaceutical Technology
MARCH 22, 2023
The device received Breakthrough Device Designation from the US Food and Drug Administration (FDA) in December 2020 as no standard of care for the condition existed. Healthcare providers are under pressure to address the growing issue of substance use disorders.
Expert insights. Personalized for you.
52 
Let's personalize your content